The Liquor Tau Protein and Beta Amyloid in Alzheimer’s Disease

Czech version

Authors: J. Hort ¹; L. Glosová ¹; M. Vyhnálek ¹; M. Bojar ¹; D. Škoda; M. Hladíková ^{1 2}
Authors‘ workplace: 1. Neurologická klinika 2. LF UK, Praha, 2. Ústav lékařské informatiky UK, 2. LF, Praha
Published in: Cesk Slov Neurol N 2007; 70/103(1): 30-36
Category: Original Paper

Podpořeno grantem GAČR 309/05/0693.

Overview

The authors present a Czech population based study on CSF biomarkers – total tau protein, phosphorylated tau protein and beta amyloid were examined in the group of patients with Alzheimer´s disease (AD), Frontotemporal dementia (FTD) and an age-matched cognitively intact control group. All subjects underwent brain MR and extended neuropsychological examinations to make it possible to classify the patients according to NINCDS-ADRDA criteria for probable AD and Neary criteria for FTD. There is no consensus in generally accepted normal values for all the three markers according to the published papers as the results of various studies differ. Due to this fact we assessed the normal values for our laboratory (average +-2 standard deviations) and ROC (receiver operating characteristic) curve to measure the best sensitivity and specificity for a given marker: total tau protein 355 pg/ml, phosphorylated tau protein 55 pg/ml and beta amyloid 458 pg/ml. The highest specificity provides determination of total tau protein and phosphorylated tau protein in AD, lower in FTD. The less reliable is beta amyloid. The authors have discussed these results with those yielded in other studies including the only study done on the Czech population.

Key words:
beta amyloid, total tau protein, phosphorylated tau protein, controls, Alzheimer´s disease, Frontotemporal dementi, norms, biomarkers, CSF

Sources

1. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004; 1: 213-25.

2. Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B et al. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev 2001; 122: 2005-11.

3. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-103.

4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.

5. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A et al. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 19: 256-65.

6. Andreasen N, Sjogren M, Blennow K. CSF markers for Alzheimer´s disease: total tau, phospho-tau a Abeta42. World J Biol Psychiatry 2003; 4: 147-55.

7. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52: 1555-62.

8. Maeck L, Meller J, Otto M, Stiens G, Wiltfang J, Stoppe G. Abeta peptide 1-42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neurosci Lett 2002; 333: 33-6.

9. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B et al. Cerebrospinal fluid tau and amyloid beta42 as predictors of development of Alzheimer´s disease in patients with mild cognitive impairment. Neurosci Lett 1999; 273: 5-8.

10. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C et al. Both total and phosphorylated tau are increased in Alzheimer´s disease. J Neurol Neurosurg Psychiatry 2001; 70: 624-30.

11. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 2003; 60: 1202-6.

12. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 2002; 160: 1269–78.

13. Pidrman V, Látalová K, Mareš J, Urbánek K, Herzig R, Bekárek V et al. Stanovení tau proteinu a beta-amyloidu jako možných diagnostických markerů demencí. Česk Slov Neurol N 2004; 5: 330-4.

14. Mareš J, Herzig R, Pidrman V, Urbánek K, Bekárek V, Schneiderka P, et al. Tau protein a beta-amyloid jako diagnostické markery Alzheimerovy demence. Čes a Slov Psychiat 2004; 1: 31-5.

15. Petrovitch H, White LR, Ross GW, Steinhorn SC, Li CY, Masaki KH et al. Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study. Neurology 2001; 57: 226-34.

16. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000; 55: 1613-20.

17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4.

18. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546–54.

19. Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H et al. Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol. 1997; 54: 697-703.

20. Hampel H, Burger K, Preussner JC, Zinkowski R, DeBernardis J, Kerkman D et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-3.

21. Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis 2000; 2: 199-206.

22. Perry EK, Morris CM, Court JA, Cheng A, Fairbairn AF, McKeith IG et al. Alteration in nicotine binding sites in Parkinson´s disease, Lewy body dementia and Alzheimer´s disease: possible index of early neuropathology. Neuroscience 1995; 64: 385-95.

23. Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett 2004; 363: 14-7.

24. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-81.

25. Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Theml T, Heldmann B et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-8.

26. Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17: 350-4.

27. Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002; 13: 112-8.

28. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003; 353: 57-60.